在妊娠期持续皮下给予重组人甲状旁腺素（1-34）对钙稳态的影响：病例报告。
The effect of continuous subcutaneous recombinant PTH (1-34) infusion during pregnancy on calcium homeostasis - a case report.
机构信息
Institute of Endocrinology, Sheba Medical Center, Ramat Gan, Israel.
出版信息
Gynecol Endocrinol. 2013 Sep;29(9):807-10. doi: 10.3109/09513590.2013.813473. Epub 2013 Jul 18.
OBJECTIVE
We describe calcium homeostasis during pregestation and gestation in a woman with iatrogenic hypoparathyroidism, treated with continuous subcutaneous recombinant parathyroid hormone (PTH) (1-34) infusion.
RESULTS
The requirement for PTH did not fluctuate much during pregnancy and was essential for maintaining normal calcium and phosphorus serum levels.
CONCLUSIONS
This study documents the insufficiency of PTH-related protein (PTHrP) or other gestation-related hormones to compensate for PTH deficiency in hypoparathyroid women, and the successful utilization of continuous subcutaneous recombinant PTH (1-34) infusion to achieve normal calcium homeostasis during gestation. Clinical trials with PTH replacement in such circumstances are warranted.
目的
我们描述了一位因医源性甲状旁腺功能减退症而接受持续皮下重组甲状旁腺激素（1-34）输注治疗的女性在妊娠前和妊娠期间的钙稳态。
结果
甲状旁腺激素的需求在怀孕期间波动不大，对于维持正常的钙和磷血清水平是必要的。
结论
本研究记录了甲状旁腺激素相关蛋白（PTHrP）或其他与妊娠相关的激素不足以补偿甲状旁腺功能减退女性的甲状旁腺激素缺乏，以及成功利用持续皮下重组甲状旁腺激素（1-34）输注在妊娠期间实现正常的钙稳态。在这种情况下进行甲状旁腺激素替代的临床试验是合理的。
Zotero 插件